Ilze Bāra

1.5k total citations · 1 hit paper
22 papers, 365 citations indexed

About

Ilze Bāra is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Ilze Bāra has authored 22 papers receiving a total of 365 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 3 papers in Surgery. Recurrent topics in Ilze Bāra's work include Lung Cancer Treatments and Mutations (15 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Lung Cancer Research Studies (7 papers). Ilze Bāra is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Lung Cancer Research Studies (7 papers). Ilze Bāra collaborates with scholars based in United States, Hong Kong and Switzerland. Ilze Bāra's co-authors include Federico Cappuzzo, Tony Mok, Barbara Klughammer, Howard West, Gene Grant Finley, Mark A. Socinski, Robert M. Jotte, Makoto Nishio, Peter Middel and Julien Mazières and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

Ilze Bāra

20 papers receiving 363 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer

2023 102 citations Mark A. Socinski, Robert M. Jotte et al. JAMA Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ilze Bāra United States	9	260	225	57	40	38	22	365
Guangming Tian China	10	291 1.1×	172 0.8×	63 1.1×	54 1.4×	43 1.1×	33	357
Yoshiro Nakahara Japan	12	282 1.1×	255 1.1×	55 1.0×	44 1.1×	54 1.4×	42	414
Weiheng Hu China	8	268 1.0×	154 0.7×	59 1.0×	52 1.3×	36 0.9×	35	334
Xiangjuan Ma China	9	274 1.1×	153 0.7×	62 1.1×	53 1.3×	33 0.9×	34	335
Alessandro Dal Maso Italy	10	286 1.1×	200 0.9×	71 1.2×	48 1.2×	99 2.6×	25	388
Longgang Cui China	7	297 1.1×	159 0.7×	61 1.1×	65 1.6×	72 1.9×	17	383
Alexander Golf Germany	6	332 1.3×	199 0.9×	29 0.5×	33 0.8×	65 1.7×	13	378
Giulia Grizzi Italy	12	262 1.0×	185 0.8×	82 1.4×	30 0.8×	70 1.8×	24	370
Ling Dai China	9	238 0.9×	136 0.6×	105 1.8×	53 1.3×	68 1.8×	28	347
Guzmán Alonso Spain	8	177 0.7×	161 0.7×	66 1.2×	43 1.1×	75 2.0×	34	313

Countries citing papers authored by Ilze Bāra

Since Specialization

Citations

This map shows the geographic impact of Ilze Bāra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ilze Bāra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ilze Bāra more than expected).

Fields of papers citing papers by Ilze Bāra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ilze Bāra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ilze Bāra. The network helps show where Ilze Bāra may publish in the future.

Co-authorship network of co-authors of Ilze Bāra

This figure shows the co-authorship network connecting the top 25 collaborators of Ilze Bāra. A scholar is included among the top collaborators of Ilze Bāra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ilze Bāra. Ilze Bāra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Leal, Ticiana, Qing Zhang, Daniel Sheinson, et al.. (2024). ALK testing patterns in early-stage non-small cell lung cancer: A real-world evidence study.. Journal of Clinical Oncology. 42(16_suppl). 8074–8074. 1 indexed citations

Ross, Helen J., David Kozono, James J. Urbanic, et al.. (2024). A randomized phase II trial of atezolizumab with or without tiragolumab before and after definitive chemoradiation for unresectable stage III non-small cell lung cancer (NSCLC; AFT-57).. Journal of Clinical Oncology. 42(16_suppl). TPS8123–TPS8123. 3 indexed citations

Lee, Jay M., Ciaran McNamee, Eric M. Toloza, et al.. (2023). Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives. Journal of Thoracic Oncology. 18(11). 1458–1477. 36 indexed citations

Smith, Katherine E., Wei Yu, Ilze Bāra, et al.. (2023). The Timing, Trajectory, and Incidence of Immune-Related Adverse Events in NSCLC Treated With Atezolizumab. JTO Clinical and Research Reports. 4(12). 100611–100611. 5 indexed citations

Liu, Stephen V., et al.. (2023). Treatment patterns and unmet need for patients with advanced non-small cell lung cancer and poor performance status: A real-world evidence study.. Journal of Clinical Oncology. 41(16_suppl). 9077–9077.

Toloza, Eric M., Harvey I. Pass, Bruce E. Johnson, et al.. (2023). P2.01-06 NAUTIKA1 Study: Preliminary Efficacy and Safety Data with Neoadjuvant Alectinib in Patients with Stage IB-III ALK+ NSCLC. Journal of Thoracic Oncology. 18(11). S297–S298. 8 indexed citations

Socinski, Mark A., Robert M. Jotte, Federico Cappuzzo, et al.. (2023). Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer. JAMA Oncology. 9(4). 527–527. 102 indexed citations breakdown →

Lee, J., Ignacio I. Wistuba, Wenjuan Yu, et al.. (2021). P03.04 Phase II Study of TKIs as Neo(adjuvant) Therapy in Stage II–III Resectable NSCLC with ALK, ROS1, NTRK or BRAFV600 Alterations. Journal of Thoracic Oncology. 16(3). S259–S260. 6 indexed citations

Socinski, Mark A., Robert M. Jotte, Federico Cappuzzo, et al.. (2021). Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150.. Journal of Clinical Oncology. 39(15_suppl). 9002–9002. 18 indexed citations

10.

Ross, Helen J., David Kozono, James J. Urbanic, et al.. (2021). AFT-16: Phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 39(15_suppl). 8513–8513. 21 indexed citations

11.

Higgins, Kristin, Walter J. Curran, Stephen V. Liu, et al.. (2020). Patterns of Disease Progression after Carboplatin/Etoposide + Atezolizumab in Extensive-Stage Small-Cell Lung Cancer (ES-SCLC). International Journal of Radiation Oncology*Biology*Physics. 108(5). 1398–1398. 18 indexed citations

12.

Cappuzzo, Federico, Martin Reck, Mark A. Socinski, et al.. (2020). IMpower150: Exploratory analysis of brain metastases development.. Journal of Clinical Oncology. 38(15_suppl). 9587–9587. 9 indexed citations

13.

Ross, Helen J., David Kozono, James J. Urbanic, et al.. (2020). AFT-16: Phase II trial of atezolizumab before and after definitive chemoradiation (CRT) for unresectable stage III non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 38(15_suppl). 9045–9045. 9 indexed citations

14.

Socinski, Mark A., Robert M. Jotte, Federico Cappuzzo, et al.. (2019). IMpower150: Analysis of efficacy in patients (pts) with liver metastases (mets).. Journal of Clinical Oncology. 37(15_suppl). 9012–9012. 6 indexed citations

15.

Ross, Helen J., David Kozono, James J. Urbanic, et al.. (2018). Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC.. Journal of Clinical Oncology. 36(15_suppl). TPS8585–TPS8585. 5 indexed citations

16.

Ross, Helen J., David Kozono, James J. Urbanic, et al.. (2017). P3.04-003 Phase II Trial of Atezolizumab Before and After Definitive Chemoradiation for Patients with Unresectable Stage III NSCLC. Journal of Thoracic Oncology. 12(11). S2285–S2286.

17.

Peters, Solange, Tony Mok, M. Pérol, et al.. (2014). Randomised, Multicentre, Phase Iii, Open-Label Study of Alectinib Vs Crizotinib in Treatment-Naïve Anaplastic Lymphoma Kinase (Alk)-Positive Advanced Nsclc (Alex Study). Annals of Oncology. 25. iv469–iv469. 1 indexed citations

18.

Mazières, Julien, Wolfram Brugger, Federico Cappuzzo, et al.. (2013). Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: Re-analysis of the SATURN study. Lung Cancer. 82(2). 231–237. 78 indexed citations

19.

Paz‐Ares, Luis, Denis Soulières, Barbara Klughammer, et al.. (2012). Pooled Analysis of Clinical Outcomes for Patients with EGFR Mutations in Non-Small-Cell Lung Cancer: An Update. Annals of Oncology. 23. ix411–ix411. 3 indexed citations

20.

Martínez‐Alonso, Montserrat, et al.. (2010). [Intestinal invagination: change in its incidence from 1987 to 2008].. PubMed. 23(4). 206–10. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact